The following article is a part of conference coverage from Psych Congress 2021 , held October 29th through November 1, 2021, in San Antonio, Texas. The team at Psychiatry Advisor will be reporting on the latest news and research conducted by leading experts in psychiatry. Check back for more from the Psych Congress 2021.
Long-acting injectable (LAI) antipsychotics were found to be associated with fewer emergency department (ED) visits and inpatient days among patients with schizophrenia re-engaging in care, according to study results recently presented at Psych Congress 2021, held from October 29 to November 1, 2021, in San Antonio, Texas.
Investigators identified 13,444 adults with schizophrenia via multistate Medicaid data. Participants re-engaged in care were defined as initiating treatment with oral antipsychotics following 12 months without schizophrenia-related hospitalizations or antipsychotic claims. Patient cohorts were classified by 4 LAI initiation strategies: adherent to oral antipsychotics without schizophrenia-related hospitalization (n=1759), nonadherent to oral antipsychotics without schizophrenia-related hospitalization (n=7211), 1 schizophrenia-related hospitalization prior to LAI initiation (n=2111), and at least 2 schizophrenia-related hospitalizations prior to LAI initiation (n=2363). Study outcomes compared the number of all-cause days of an inpatient stay and ED visits.
Patients with adherence to oral antipsychotics had 43% fewer inpatient days compared with the nonadherent cohort, 69% fewer than patients with 1 hospitalization, and 80% fewer than patients with at least 2 hospitalizations (all P <.05). Patients with adherence to oral antipsychotics also had 57% fewer ED visits compared with the nonadherent cohort, 59% fewer than patients with 1 hospitalization, and 79% fewer than patients with at least 2 hospitalizations (all P <.05). Patients with nonadherence to oral antipsychotics had 42% and 64% fewer inpatient days (all P <.05), and 2% (P =.946) and 52% (P <.05) fewer ED visits compared with patients with 1 or at least 2 hospitalizations prior to LAI initiation, respectively.
According to the investigators, patients with schizophrenia who initiated LAI antipsychotics earlier were associated with fewer inpatient days and ED visits. The researchers indicated that future guidelines pertaining to LAI use may be informed by these findings.
Disclosure: This clinical trial was supported by Janssen Scientific Affairs, LLC. Please see the original reference for a full list of authors’ disclosures.
Visit Psychiatry Advisor’s meetings section for complete coverage of Psych Congress 2021.
Lin D, Correll C, Benson C, et al. A comparison of clinical outcomes in Medicaid beneficiaries with schizophrenia following different long-acting injectable antipsychotic initiation strategies. Presented at: Psych Congress 2021; October 29-November 1, 2021; San Antonio, TX. Abstract 154.